- Home
- PRME vs OLMA Comparison
PRME vs OLMA Comparison
Compare PRME & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- OLMA
- Stock Information
- Founded
- PRME 2019
- OLMA 2006
- Country
- PRME United States
- OLMA United States
- Employees
- PRME N/A
- OLMA N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- OLMA Health Care
- Exchange
- PRME Nasdaq
- OLMA Nasdaq
- Market Cap
- PRME 784.4M
- OLMA 725.5M
- IPO Year
- PRME 2022
- OLMA 2020
- Fundamental
- Price
- PRME $3.77
- OLMA $8.26
- Analyst Decision
- PRME Buy
- OLMA Strong Buy
- Analyst Count
- PRME 6
- OLMA 6
- Target Price
- PRME $9.50
- OLMA $23.00
- AVG Volume (30 Days)
- PRME 3.8M
- OLMA 1.4M
- Earning Date
- PRME 11-07-2025
- OLMA 11-07-2025
- Dividend Yield
- PRME N/A
- OLMA N/A
- EPS Growth
- PRME N/A
- OLMA N/A
- EPS
- PRME N/A
- OLMA N/A
- Revenue
- PRME $5,977,000.00
- OLMA N/A
- Revenue This Year
- PRME $179.58
- OLMA N/A
- Revenue Next Year
- PRME N/A
- OLMA N/A
- P/E Ratio
- PRME N/A
- OLMA N/A
- Revenue Growth
- PRME 647.13
- OLMA N/A
- 52 Week Low
- PRME $1.11
- OLMA $2.86
- 52 Week High
- PRME $6.94
- OLMA $13.06
- Technical
- Relative Strength Index (RSI)
- PRME 36.50
- OLMA 44.49
- Support Level
- PRME $4.13
- OLMA $7.76
- Resistance Level
- PRME $5.03
- OLMA $8.41
- Average True Range (ATR)
- PRME 0.43
- OLMA 0.59
- MACD
- PRME -0.18
- OLMA -0.12
- Stochastic Oscillator
- PRME 8.74
- OLMA 34.02
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.